公开(公告)号：EP1427421A1

公开(公告)日：2004-06-16

申请号：EP02773237.9

申请日：2002-08-22

申请人： Amgen Inc.

发明人： HARMANGE, Jean-Christophe ,  BOOKER, Shon ,  BUCHANAN, John, L. ,  CHAFFEE, Stuart ,  NOVAK, Perry, M. ,  VAN DER PLAS, Simon ,  ZHU, Xiaotian ,  NAPIER, Spencer, Charles,R.

IPC分类号： A61K31/506 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D417/14 ,  C07D405/14 ,  C07D403/12 ,  C07D403/14

CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

摘要： The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.

公开(公告)号：EP1418916A1

公开(公告)日：2004-05-19

申请号：EP02766079.4

申请日：2002-08-22

申请人： Amgen Inc.

发明人： BUCHANAN, John, L. ,  CHAFFEE, Stuart ,  HARMANCE, Jean-Christophe ,  NOVAK, Perry, M. ,  ZHU, Xiaotian

IPC分类号： A61K31/506 ,  A61P35/00 ,  C07D413/14 ,  C07D413/12 ,  C07D417/14 ,  C07D417/12

CPC分类号： C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

摘要： Compounds of Formula (I) are claimed, wherein R1 is a heteroaryl ring containing at least one oxygen of sulfur heteroatom and R2 is as defined in the claims. These compounds are useful in the treatment of cancer.

公开(公告)号：EP1144390A2

公开(公告)日：2001-10-17

申请号：EP00905700.1

申请日：2000-01-21

申请人： Amgen Inc.,

发明人： ARMISTEAD, David, M. ,  BEMIS, Jean, E. ,  ELBAUM, Daniel ,  HABGOOD, Gregory ,  NOVAK, Perry, M. ,  NUNES, Joseph, J. ,  TOLEDO-SHERMAN, Leticia, M.

IPC分类号： C07D239/47 ,  C07D239/88 ,  C07D239/93 ,  C07D239/95 ,  A61K31/513 ,  A61K31/517 ,  A61P11/00 ,  A61P25/00 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07D239/47 ,  C07D239/56 ,  C07D239/70

摘要： The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.

公开(公告)号：EP1390354A1

公开(公告)日：2004-02-25

申请号：EP02733972.0

申请日：2002-04-11

申请人： Amgen Inc.

发明人： BUCHANAN, John, L. ,  KIM, Joseph, L. ,  NOVAK, Perry, M. ,  NUNES, Joseph, J. ,  PATEL, Vinod, F.

IPC分类号： C07D251/18 ,  C07D403/12 ,  A61K31/53 ,  A61P35/00 ,  C07D401/14 ,  C07D401/12

CPC分类号： C07D401/12 ,  C07D251/18 ,  C07D401/14 ,  C07D403/12

摘要： The invention encompasses compounds of formula I, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer and polycystic kidney disease.

公开(公告)号：EP1218360A1

公开(公告)日：2002-07-03

申请号：EP00972036.8

申请日：2000-10-06

申请人： Amgen Inc.,

发明人： ARMISTEAD, David, M. ,  BEMIS, Jean, E. ,  BUCHANAN, John, L. ,  DIPIETRO, Lucian, V. ,  ELBAUM, Daniel ,  HABGOOD, Gregory, J. ,  KIM, Joseph, L. ,  MARSHALL, Teresa, L. ,  GEUNS-MEYER, Stephanie, D. ,  NOVAK, Perry, M. ,  NUNES, Joseph, J. ,  PATEL, Vinod F. ,  TOLEDO-SHERMAN, Leticia, M. ,  ZHU, Xiaotian

IPC分类号： C07D251/22 ,  C07D403/12 ,  A61P43/00 ,  C07D251/16 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D405/04 ,  C07D401/14 ,  C07D405/14

CPC分类号： C07D401/04 ,  C07D251/18 ,  C07D251/22 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： The invention relates to inhibitors of formula (I) of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making phosphoryl transferase inhibitor compounds, methods of inhibiting phosphoryl transferase activity, and methods for treating disease or disease symptoms. In formula (I), each R?1 and R2¿ is independently R?3; R8; NHR3; NHR5; NHR6; NR5R5; NR5R6; SR5; SR6; SR3; OR5; OR6; OR3; C(O)R3¿; heterocyclyl optionally substituted with 1-4 independent R4 on each ring; or C1-C10 alkyl substituted with 1-4 independent R?4; R3, R4, R5, R6, R8¿ are as defined in the application.

公开(公告)号：EP1218360B1

公开(公告)日：2008-05-28

申请号：EP00972036.8

申请日：2000-10-06

申请人： Amgen Inc.,

发明人： ARMISTEAD, David, M. ,  BEMIS, Jean, E. ,  BUCHANAN, John, L. ,  DIPIETRO, Lucian, V. ,  ELBAUM, Daniel ,  HABGOOD, Gregory, J. ,  KIM, Joseph, L. ,  MARSHALL, Teresa, L. ,  GEUNS-MEYER, Stephanie, D. ,  NOVAK, Perry, M. ,  NUNES, Joseph, J. ,  PATEL, Vinod F. ,  TOLEDO-SHERMAN, Leticia, M. ,  ZHU, Xiaotian

IPC分类号： C07D251/22 ,  C07D403/12 ,  A61P43/00 ,  C07D251/16 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04 ,  C07D405/04 ,  C07D401/14 ,  C07D405/14

CPC分类号： C07D401/04 ,  C07D251/18 ,  C07D251/22 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： The invention relates to inhibitors of formula (I) of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making phosphoryl transferase inhibitor compounds, methods of inhibiting phosphoryl transferase activity, and methods for treating disease or disease symptoms. In formula (I), each R?1 and R2¿ is independently R?3; R8; NHR3; NHR5; NHR6; NR5R5; NR5R6; SR5; SR6; SR3; OR5; OR6; OR3; C(O)R3¿; heterocyclyl optionally substituted with 1-4 independent R4 on each ring; or C1-C10 alkyl substituted with 1-4 independent R?4; R3, R4, R5, R6, R8¿ are as defined in the application.

公开(公告)号：EP1654238A1

公开(公告)日：2006-05-10

申请号：EP04778640.5

申请日：2004-07-15

申请人： AMGEN INC.

发明人： BUCHANAN, John, L. ,  ELBAUM, Daniel ,  MARTIN, Matthew, W. ,  MCGOWAN, David, C. ,  NOVAK, Perry, M. ,  NUNES, Joseph, J.

IPC分类号： C07D239/48 ,  C07D403/12 ,  C07D401/12 ,  C07D405/12 ,  C07D213/75 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  A61K31/505 ,  A61P37/00

CPC分类号： C04B35/632 ,  C07D213/75 ,  C07D239/48 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04

摘要： The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula (1) and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.